Drugs / High-dose influenza virus vaccine
High-dose influenza virus vaccine
also known as
High-dose quadrivalent influenza virus vaccine (QIV HD2)
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02553343 | Sep 2015 → Apr 2016 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | High-dose influenza virus vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02553343 ↗ |
| Known as | High-dose quadrivalent influenza virus vaccine (QIV HD2) | “High-dose quadrivalent influenza virus vaccine (QIV HD2)” NCT02553343 ↗ |
| Modality | Vaccine | “high-dose quadrivalent influenza vaccine” NCT02553343 ↗ |
| Route | Intramuscular | “0.5 mL, Intramuscular (IM), injected into the deltoid area” NCT02553343 ↗ |